Aurobindo Recalls Lisinopril Tablets Due to Labeling Error
Aurobindo Pharma USA Inc is recalling specific lots of Lisinopril 30 mg tablets because the label displays the incorrect strength on the side panel.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which is defined as unlikely to cause adverse health consequences. The issue is a minor labeling error regarding the displayed strength, which falls under the 'Low' severity criteria for cosmetic or documentation issues.
Plain-English summary
Aurobindo Pharma USA Inc is recalling 1,776 bottles of Lisinopril Tablets, USP, 30 mg. The recall is due to a labeling error where the side display panel of the label lists an incorrect strength. The affected product is a prescription-only medication manufactured by Aurobindo Pharma Limited in India and distributed nationwide.
The recall involves two specific lots: Lot KP3012001-A and Lot KP3012002-A, both with an expiration date of 12/13. The product is identified by NDC 65862-041-01. The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences.
Consumers who have this medication should check the lot number and expiration date on their bottles. If the product matches the recalled lots, they should contact their pharmacist or healthcare provider for guidance on how to proceed.
The recalled product
- Product
- LISINOPRIL (LISINOPRIL)
- Brand
- LISINOPRIL
- Manufacturer
- Aurobindo Pharma USA Inc
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 1,776
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot KP3012001-A Exp.12/13 Lot KP3012002-A Exp.12/13
UPCs (3)
- 0365862037015
- 0365862038012
- 0365862040015
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LISINOPRIL
- HighLisinopril 10 mg Tablets Recalled for Metal Fragment Contamination
FDA (Drugs) · 2024-11-27
- HighLisinopril Tablets Recalled for Embedded Metal Contamination
FDA (Drugs) · 2022-09-21
- HighLupin Recalls Lisinopril Tablets Due to Foreign Tablet Presence
FDA (Drugs) · 2020-08-05
- HighLupin Recalls Lisinopril 5 mg Tablets Due to Product Mix-Up
FDA (Drugs) · 2020-06-17
- ModerateLupin Recalls Lisinopril Tablets Due to Foreign Tablet Mix-Up
FDA (Drugs) · 2020-04-08
Same manufacturer · Aurobindo Pharma USA Inc
See all →- ModerateDicyclomine Hydrochloride Capsules Recalled for Empty Capsules
FDA (Drugs) · 2026-08-12
- ModerateAmazon Basic Care Acetaminophen 325 mg Tablets Recalled Due to Discoloration
FDA (Drugs) · 2025-06-25
- HighPrescription drug recall: Aurobindo Nebivolol tablets contain excess nitrosamine impurity
FDA (Drugs) · 2024-12-25
- HighPrescription Cinacalcet Tablets Recalled for N-Nitroso Impurity
FDA (Drugs) · 2024-12-11
- HighFDA Recalls Cinacalcet 30mg Tablets for N-nitroso Impurity
FDA (Drugs) · 2024-12-11
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02